Diabetic retinopathy is a major complication of diabetes associated with vascular and neuronal abnormalities, leading to severe visual dysfunction ([@B1][@B2]--[@B3]). Recent studies have emphasized the importance of diabetes-induced neuronal damage in the retina at an early stage of disease progression ([@B2],[@B3][@B4][@B5][@B6]--[@B7]). The apoptotic cells due to diabetes are likely to include retinal ganglion cells (RGCs) and other neurons ([@B8]). Therefore, the identification of pharmacological targets for the prevention of damage to RGCs from diabetes may provide a potential therapeutic strategy for diabetes-induced vision loss.

Ca^2+^/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine-threonine protein kinase that is implicated in a variety of neuronal functions ([@B9][@B10]--[@B11]). Recently, it was found that CaMKII contributes to the death of neuronal cells, including RGCs ([@B10],[@B12][@B13]--[@B14]). However, CaMKII also promotes neuronal survival in response to various stresses ([@B15],[@B16]), and thus it has been proposed that CaMKII is an important point of intersection for different pathways involved in neuron-destroying diseases, including diabetic retinopathy.

For prevention of vision loss due to neuronal and vascular damage, topical or oral treatments with ocular penetration are ideal therapies that have been developed recently; in addition, several clinical studies have concentrated on the beneficial effects of natural polyphenols, such as resveratrol ([@B17],[@B18]). Resveratrol is a plant-derived phytoalexin with diverse health benefits, including protection from metabolic disorders, such as diabetes ([@B19][@B20]--[@B21]). Although many studies have shown neuroprotective effects of resveratrol in in vitro experimental optic neuropathy ([@B22],[@B23]), the effects of resveratrol on retinal neuron damage due to diabetes are not known. Therefore, we investigated whether resveratrol affects CaMKII-dependent RGC death in diabetic mice and found that resveratrol can suppress CaMKII induction and thereby decrease the extent of RGC death. Our results suggest that resveratrol may have powerful therapeutic applications for prevention of CaMKII-mediated RGC death in diabetic retinopathy.

RESEARCH DESIGN AND METHODS
===========================

Animals.
--------

Male C57BL/6 mice (Samtako, Osan, Korea), weighing 20--22 g (8 weeks old), were used in this study. All mice were maintained on a standard rodent diet (20% protein, 4.5% fat, 6% cellulose, and 7.25% ash \[containing 1.2% calcium and 0.62% phosphorus\] \[\#5057; Purina, Kyeonggi-Do, Korea\]) and water ad libitum and were handled in strict accordance with the Institutional Animal Care and Use Committee of Gyeongsang National University.

For induction of diabetes, mice were injected intraperitoneally with 55 mg/kg streptozotocin (STZ; Sigma, St. Louis, MO) dissolved in 50 mmol/l sodium citrate (pH 4.5), once a day for 5 consecutive days, and sex- and age-matched control mice received buffer alone. All mice were killed 2 months after the injections. Blood samples were obtained by tail puncture after a 2-h fasting period, and the blood glucose levels were measured using a glucometer (Precision, U.K.). Diabetes was confirmed by blood glucose levels \>13.9 mmol/l, 1 week after the fifth injection of STZ. Body weights and blood glucose levels in mice were recorded every 2 weeks.

Administration of resveratrol.
------------------------------

Resveratrol (*trans*-3,4′,5-trihydroxystilbene; category R5010; Sigma; 20 mg/kg) was suspended in 0.5% carboxymethylcellulose (CMC; Sigma) dissolved in 0.9% saline. This solution was administered by oral gavage once a day for 4 weeks, beginning 1 month after the fifth injection of STZ or buffer, and 0.5% CMC was given as a control. Finally, mice were assigned to four groups (that is, control and diabetic mice treated with either CMC or resveratrol, respectively). After the treatments, changes in body weights and blood glucose levels were recorded every 2 weeks.

Assay kits and antibodies.
--------------------------

To detect cell death, we used terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay kits with two different detection modes: Converter-POD and TMR red (In Situ Cell Death Detection kits; Roche, Mannheim, Germany, respectively). CaMKII activity was examined using the CaMKII Kinase Assay Kit from Upstate (Temecula, CA), and an enhanced chemiluminescent (ECL) kit was obtained from Amersham Biosciences (Little Chalfont, U.K.). Mouse and rabbit monoclonal antibodies to CaMKII, phospho-CaMKII (T286), active caspase-3, and gamma synuclein (γ-Syn; the ganglion cell marker) were purchased from Abcam (Cambridge, U.K.). Mouse monoclonal antibodies against α-tubulin and pro-caspase-3 were obtained from Sigma. Secondary horseradish peroxidase (HRP)-conjugated anti-mouse and -rabbit IgGs for Western blotting, a biotinylated anti-rabbit IgG for immunohistochemistry, and Qdot 525 goat F(ab′)~2~ and Alexa Fluor 594 goat anti-mouse IgGs or Alexa Fluor 350 and 488 goat anti-rabbit IgGs for immunofluorescent staining were purchased from Pierce (Rockford, IL), Molecular Probes (Eugene, OR), Vector Laboratories (Burlingame, CA), and Invitrogen (Carlsbad, CA), respectively.

Western blot analysis.
----------------------

Protein extraction and Western blot analyses were performed as described previously ([@B24]). Total protein (30 μg) from the retinas of each group of mice was subjected to 10% SDS-PAGE and then transferred to a nitrocellulose membrane (Millipore). The blots were incubated consecutively in primary antibody against CaMKII, phospho-CaMKII, and pro- or active caspase-3 as well as an HRP-conjugated anti-rabbit IgG, and the target proteins were visualized using an enhanced chemiluminescent kit. Each blot was reprobed with α-tubulin and pro-caspase-3 to control for differences in loading. The fold changes in protein levels compared with controls, normalized to α-tubulin or pro-caspase-3, are indicated below the blots and as a bar graph. Data are representative of four independent tests.

Measurement of changes in retinal morphology.
---------------------------------------------

Two months after injection of STZ or buffer, 10-μm frozen retinal sections were prepared as described previously ([@B25]). To assess retinal morphological changes, the sections were stained with hematoxylin and eosin (H&E), and retinal thickness was measured as the length (μm) from the ganglion cell layer (GCL) to the tip of the inner nuclear layer. A comparative analysis of the retinal thicknesses in diabetic and control groups was performed using four different fields in four different regions of each retina.

Immunohistochemical staining.
-----------------------------

Immunohistochemistry was performed in the sectioned retinas as described previously ([@B25]). After blocking with serum, the sections were incubated in primary antibody against CaMKII or phospho-CaMKII, a biotinylated secondary anti-rabbit IgG, and an avidin-biotinylated HRP complex (ABC; Vector Laboratories), consecutively. To visualize immunoreactivity to CaMKII, the sections were developed using 0.025% 3,3′-diaminobenzidine tetrahydrochloride (DAB; Sigma)/0.003% H~2~O~2~ and counterstained with cresyl violet to dye neuronal cells. To confirm whether the immunopositive cells of CaMKII and phospho-CaMKII were RGCs, we performed double-immunofluorescent staining as described previously ([@B24]) for CaMKII or phospho-CaMKII and γ-Syn. Retinal sections were incubated consecutively in Image-iT FX signal enhancer (Molecular Probes) for 10 min, a mixture of primary antibodies for 2 h, and a mixture of Alexa Fluor 350 and 594 goat anti-rabbit and mouse IgGs for 1 h. The sections were then counterstained with the nuclear marker 40,6-diamidino-2-phenylindole dihydrochloride (DAPI; Invitrogen) and wet-mounted in ProLong Gold antifade reagent (Invitrogen).

Evaluation of cell death using TUNEL assays.
--------------------------------------------

Cell death was analyzed in the retinal cryosections using the TUNEL assay kit with Converter-POD according to the manufacturer\'s directions. The sections were fixed in 10% fresh formaldehyde for 20 min at room temperature, washed three times in 100 mmol/l PBS (PBS; pH 7.4) for 3 min, incubated in blocking solution (3% H~2~O~2~ in methanol) for 10 min, permeabilized in 0.1% Triton X-100 with 0.1% sodium citrate in PBS for 5 min on ice, and washed again in PBS. The fixed and permeabilized sections were covered with parafilm and consecutively incubated in the TUNEL reaction mixture for 1 h and Converter-POD for 30 min at 37°C. After washing in PBS, the signal-converted sections were developed using DAB substrate with H~2~O~2~ in PBS and counterstained with cresyl violet. To confirm whether the TUNEL-positive cells are RGCs or phospho-CaMKII--immunopositive cells, we sequentially performed immunofluorescent staining as described previously ([@B24]) for γ-Syn and phospho-CaMKII and the TUNEL assay with TMR red according to the manufacturer\'s directions on the same cryosections. Retinal sections were incubated consecutively in signal enhancer, primary antibody for γ-Syn, and phospho-CaMKII for 2 h and Alexa Fluor 488 goat anti-rabbit IgG for 1 h. The sections were then stained with the TUNEL reaction and counterstained with DAPI. To determine the correlation between RGC death and CaMKII or phospho-CaMKII expression, double-immunofluorescent staining for CaMKII or phospho-CaMKII and γ-Syn, using Qdot 525 and Alexa Fluor 350 goat anti-mouse and rabbit IgGs and the TUNEL reaction, were sequentially performed as mentioned above. All reactions were performed in a moist chamber to prevent evaporative loss. The total number of TUNEL- and CaMKII or phospho-CaMKII--positive RGCs was counted in the GCL (∼100 μm) in four different fields from three different retinas for each group.

Knockdown and inactivation of CaMKII.
-------------------------------------

For knockdown of CaMKII, we performed target gene silencing with a small-interfering RNA (siRNA). The sequence of αCaMKII siRNA for silencing the mouse CaMKII was designed using the Turbo si-Designer program (Bioneer; Daedeok-gu, Daejeon, Korea), and the siRNA duplex was purchased from Bioneer. The sense and antisense sequences of the siRNA were as follows: 5′-UGAUCGAAGCCAUAAGCAA(dTdT)-3′ (sense) and 5′-UUGCUUAUGGCUUCGAUCA(dTdT)-3′ (antisense). The siRNA duplex was completely dissolved in RNase-free distilled water at a final concentration of 1 mmol/l and diluted again to 1/10 and 1/100 (0.1 and 0.01 mmol/l). To select the best condition for siRNA gene silencing, 2 μl each siRNA diluent were carefully injected into the right vitreous humors of mice 2 months after induction of diabetes, and 2 μl distilled water was injected into the left vitreous humors as controls as described previously ([@B7]). Mice were killed 0, 1, 2, and 4 days after the injections, and the efficiency of the siRNA was determined by Western blotting of CaMKII. Data are representative of four independent tests.

To examine the effects of CaMKII inhibition, a myristoylated autocamtide-2--related inhibitory peptide (AIP) (Biomol, Plymouth Meeting, PA), a highly specific and potent inhibitor of CaMKII, was completely dissolved in sterile PBS (pH 7.4) at a final concentration of 500 μmol/l. AIP (2 μl) was injected into the right vitreous humors of mice 2 months after induction of diabetes, and PBS was injected into the left vitreous humors as controls. The efficiency of the AIP was determined by Western blotting of CaMKII 0, 1, 2, and 4 days after the injection. Data are representative of four independent tests.

Finally, 1 mmol/l siRNA or 500 μmol/l AIP was injected intravitreally into the retinas of mice 2 months after injection of STZ or buffer, and changes in the expression levels of CaMKII and phospho-CaMKII, the kinase activity of CaMKII, and the extent of cell death by CaMKII knockdown and inhibition were evaluated after 2 days of treatment.

CaMKII kinase assay.
--------------------

CaMKII kinase activity was analyzed in 100 μg total protein from each retina by the CaMKII Kinase Assay Kit (Upstate) according to the manufacturer\'s directions with autocamtide-3 as a specific substrate for CaMKII. CaMKII was stimulated with buffer containing 40 mmol/l HEPES, 1 mmol/l Mg-acetate, 100 μmol/l EGTA, 200 μmol/l Ca^2+^, 50 μmol/l ATP, and 10 μmol/l calmodulin. The reaction was initiated by the addition of calmodulin and terminated by the addition of 1 mmol/l EGTA at the indicated times. The results are reported as total enzyme activity in the presence of exogenous Ca^2+^ and calmodulin and expressed in picomoles phosphate incorporated into autocamtide-3 per minute per milligram total retinal protein. Four independent tests were repeated in different retinal extracts for each group.

Image capture and statistical analyses.
---------------------------------------

All retinal images were captured at a distance of ∼0.8--1 mm from the optic nerve head using an IX2-DSU disk scanning biological microscope (Olympus, Wendenstrasse, Hamburg, Germany). Quantitative analyses were performed using the Soft Imaging System (System, Münster, Germany) and SigmaGel 1.0 software (Jandel Scientific, Erkrath, Germany), and bar graphs were constructed using SigmaPlot 4.0 (SPSS, Chicago, IL). All data are representative of four independent values and presented as means ± SE. Statistical analyses were performed nonparametrically using the Kruskal-Wallis *H* test and the Mann-Whitney *U* test (SPSS). A *P* value of \<0.05 was considered statistically significant.

RESULTS
=======

Control mice exhibited a sustained increase in body weight (g) from the beginning to the end of the study period (21.5 ± 0.38 to 29.4 ± 0.55, *P* \< 0.05, *n* = 10), but diabetic mice showed no significant change in weight (data not shown). The blood glucose levels (mmol/l) of diabetic mice increased markedly and steadily from 1 week to 2 months after induction of diabetes (23.3 ± 1.53 to 31.2 ± 0.87, *n* = 10, respectively), although control mice remained normoglycemic throughout the study. Administration of resveratrol and CMC did not affect the body weights of diabetic or control mice, or the blood glucose levels of control mice; however, hyperglycemia was significantly decreased in resveratrol-treated diabetic mice compared with CMC-treated diabetic mice after 2 months (31.2 ± 0.84 vs. 27.7 ± 1.16 mmol/l; *P* \< 0.05, *n* = 10) ([Table 1](#T1){ref-type="table"}).

###### 

Changes in body weight and blood glucose level with resveratrol treatment

           Body weight (g)   Blood glucose (mmol/l)                                                                  
  -------- ----------------- ------------------------ ------------ ------------ ----------- ----------- ------------ ---------------------------------------------
  Week 0   28.3 ± 0.3        27.7 ± 0.5               21.2 ± 0.5   20.4 ± 0.4   8.7 ± 0.1   9.0 ± 0.3   25.4 ± 0.8   27.5 ± 0.9
  Week 2   27.6 ± 0.3        26.3 ± 0.4               21.1 ± 0.6   21.1 ± 0.5   9.0 ± 0.2   7.4 ± 0.2   31.8 ± 0.7   29.6 ± 0.8
  Week 4   28.5 ± 0.3        27.8 ± 0.4               20.6 ± 0.6   21.2 ± 0.5   8.3 ± 0.2   7.9 ± 0.2   31.2 ± 0.8   27.7 ± 1.2[\*](#TF1-1){ref-type="table-fn"}

Data are means ± SE (*n* = 10). Resveratrol (in 0.5% CMC) at a dose of 20 mg/kg of body weight and 0.5% CMC alone were administered daily to control and diabetic mice, respectively, by oral gavage for 4 weeks. Time points were 0, 2, and 4 weeks after administration of resveratrol and CMC to control and diabetic mice, respectively, 1 month after STZ treatment: C-C and C-R, CMC- and resveratrol-treated control mice, respectively; D-C and D-R, CMC- and resveratrol-treated diabetic mice, respectively.

\**P* \< 0.05 compared with CMC- and resveratrol-treated diabetic groups.

In H&E staining, mice showed a significant decrease (*P* \< 0.05, *n* = 4) in the thicknesses of the inner retina, from the GCL to the tip of the inner nuclear layer, by 13.3% 2 months after induction of diabetes compared with those of controls ([Fig. 1](#F1){ref-type="fig"}*C*). No diabetes-induced changes were observed in the thicknesses of the outer retinal regions (data not shown). In Western blot analysis of active caspase-3 to confirm cell death, protein levels were highly increased (2.5-fold; *P* \< 0.05, *n* = 4) in the retinas of diabetic mice compared with controls ([Fig. 1](#F1){ref-type="fig"}*D* and *E*). TUNEL-positive signals were observed in the GCLs of the diabetic retinas (arrows in [Fig. 1](#F1){ref-type="fig"}*G*) compared with controls ([Fig. 1](#F1){ref-type="fig"}*F*) and specific to RGCs (arrows in [Fig. 1](#F1){ref-type="fig"}*J*). The number of TUNEL-positive RGCs was greatly increased (4.4-fold; *P* \< 0.05, *n* = 4) in the diabetic retinas compared with controls ([Fig. 1](#F1){ref-type="fig"}*K*).

![Determination of retinal thickness and neuronal cell death in retinas of mice 2 months after induction of diabetes compared with control mice. For morphological analysis, H&E staining was performed on 10-μm retinal cryosections of control (*A*) and diabetic (*B*) mice. Retinal thickness was measured as the length (in μm) from the GCL to the tip of the INL, and the results were obtained from comparative analysis of four different images of each retina (*C*). To assess cell death induced by diabetes in the retinas, Western blotting using an antibody to active caspase-3 was performed for the retinas of both groups (*D*). An immunoblot with an antibody to active caspase-3 was reprobed with an antibody to pro-caspase-3 to control for differences in loading, and the level of each protein was normalized to that of pro-caspase-3. Four independent tests were repeated in different retinal extracts from each group, and the results are indicated as the fold change (*E*). To investigate retinal neuron death, the TUNEL assay was performed on retinal sections from control and diabetic mice, followed by counterstaining with cresyl violet (*F* and *G*). To confirm the death of RGCs, immunofluorescent staining of γ-Syn, the GC marker, using Alexa Fluor 488 goat anti-rabbit IgG (*green*) and TUNEL staining were performed consecutively on the same sections from diabetic mice, and the sections were counterstained with the nuclear marker DAPI (*H--J*). The total number of TUNEL^+^ RGCs was counted in four different fields of the GCL (∼100 μm) from three different retinas of each group (*K*). Data are means ± SE (*n* = 4). \**P* \< 0.05 comparing control and diabetic groups. CTL and DM, control and diabetic mice 2 months after injection of buffer or STZ; INL, inner nuclear layer; IPL, inner plexiform layer; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer. Bars, 12.5 μm. (A high-quality digital representation of this figure is available in the online issue.)](zdb0071062000001){#F1}

In Western blotting with CaMKII antibody, we observed two bands (∼45 and 54 kDa) for CaMKII protein ([Fig. 2](#F2){ref-type="fig"}*A*), indicating its α and β forms, and the molecular level of CaMKII was considered the total amount of both forms. Protein levels of both CaMKII and phospho-CaMKII (∼50 kDa) were greatly increased (2.9- and 2.6-fold; *P* \< 0.05, *n* = 4, respectively) in the retinas of diabetic mice compared with controls ([Fig. 2](#F2){ref-type="fig"}*A--C*). Likewise, CaMKII kinase activity was significantly greater (2.03-fold; *P* \< 0.05, *n* = 4) in the retinas of diabetic mice than in controls ([Fig. 2](#F2){ref-type="fig"}*D*). Immunoreactivities of CaMKII and phospho-CaMKII increased in the GCLs of diabetic retinas (arrows in [Fig. 2](#F2){ref-type="fig"}*F* and *H*) compared with controls ([Fig. 2](#F2){ref-type="fig"}*E* and *G*) and were specific to RGC cells (arrowheads in inserts) ([Fig. 2](#F2){ref-type="fig"}*F* and *H*).

![Molecular and morphological expression of CaMKII and phospho-CaMKII (Thr286), and CaMKII kinase assay in retinas of mice 2 months after induction of diabetes compared with controls. Protein levels of CaMKII and phospho-CaMKII were assessed by Western blotting using 30 μg total protein from each retina, and representative blots from four independent Western blots are shown in *A*. The immunoblots were reprobed with α-tubulin to control for differences in loading, and levels of each protein were normalized to that of α-tubulin. The results indicate the fold change in *B* and *C*, respectively. Analysis of CaMKII kinase activity was performed in the same retinal homogenates (100 μg) prepared for immunoblotting using the CaMKII Kinase Assay Kit. The results are expressed as picomoles of phosphate incorporated into the CaMKII substrate peptide per minute per milligram total protein, and four independent tests were repeated with different retinal extracts for each group (*D*). Data are means ± SE (*n* = 4). \**P* \< 0.05 comparing control and diabetic groups. To confirm the distribution of CaMKII (*E* and *F*) and phospho-CaMKII (*G* and *H*) in retinal neuronal cells from control and diabetic mice, retinal cryosections were immunostained with each antibody and then counterstained with cresyl violet. Arrows indicate immunopositive signals of CaMKII and phospho-CaMKII in the GCL of the diabetic retina, and arrowheads in each insert show the double-immunofluorescent staining of γ-Syn and CaMKII or phospho-CaMKII, using Alexa Fluor 350 (*blue*) and 594 (*red*) goat anti-rabbit and mouse IgGs (*F* and *H*). CTL and DM, control and diabetic groups 2 months after injection of buffer or STZ; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer. Bars, 12.5 μm. (A high-quality digital representation of this figure is available in the online issue.)](zdb0071062000002){#F2}

[Figure 3](#F3){ref-type="fig"} shows that not only were all TUNEL-positive cells RGCs but also the apoptotic RGCs were CaMKII or phospho-CaMKII immunopositive in the retinas of diabetic mice (arrows in [Fig. 3](#F3){ref-type="fig"}*B* and *E*), while the RGCs of control mice were not ([Fig. 3](#F3){ref-type="fig"}*A* and *D*). The number of RGCs co-stained for TUNEL and CaMKII or phospho-CaMKII was greater (2.8- or 5.3-fold; *P* \< 0.05, *n* = 4, respectively) in diabetic retinas than in controls ([Fig. 3](#F3){ref-type="fig"}*C* and *F*).

![Co-localization of CaMKII or phospho-CaMKII immunopositive signals and apoptotic RGC cells in retinas of mice 2 months after induction of diabetes compared with controls. To examine the correlation between CaMKII or phospho-CaMKII expression and RGC cell death, double-immunofluorescent staining for CaMKII or phospho-CaMKII and γ-Syn, the ganglion cell marker, using Qdot 525 (*green*) and Alexa Fluor 350 (*blue*) goat anti-mouse and rabbit IgGs, and TUNEL staining (*red*) were sequentially performed on the same sections. Arrows in *B* and *E* indicate TUNEL-positive RGC cells that were immunopositive for CaMKII and phospho-CaMKII in the diabetic retinas compared with control (*A* and *D*). The total number of triple-labeled cells was counted in the GCL (∼100 μm) in four different fields from three different retinas for each group (*C* and *F*). Data are means ± SE (*n* = 4). \*\**P* \< 0.001 comparing control and diabetic groups. CTL and DM, control and diabetic mice 2 months after injection of buffer or STZ; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer. Bars, 12.5 μm. (A high-quality digital representation of this figure is available in the online issue.)](zdb0071062000003){#F3}

Treatment with siRNA efficiently decreased the level of CaMKII protein in a dose- and time-dependent manner and was greatest 2 days after treatment with 1 mmol/l siRNA at the various dosages and times studied ([Fig. 4](#F4){ref-type="fig"}*A* and *B*). Interestingly, suppression of CaMKII by siRNA injection significantly reduced the level of active caspase-3 in retinas of mice 2 months after induction of diabetes; 2 days after treatment, the levels were 1.9-, 2.1-, 1.6-, and 2.5-fold lower, respectively, in siRNA-injected diabetic mice compared with mice injected with distilled water (*P* \< 0.05, *n* = 4) ([Fig. 4](#F4){ref-type="fig"}*C--F*). However, siRNA had no effect on control mice.

![Changes in CaMKII and phospho-CaMKII protein levels, kinase activity of CaMKII, and the level of active caspase-3 protein after αCaMKII knockdown using RNA interference in retinas of mice 2 months after induction of diabetes compared with controls. siRNA (2 μl) was injected into the right vitreous of the retinas, and an equal volume of distilled water was injected into the left vitreous as a control. *A* and *B*: Dose- and time-independent effects of siRNA on the level of CaMKII protein in the retinas of mice 2 months after the induction of diabetes, 2 days after injection with 0.01, 0.1, or 1 mmol/l siRNA, and 0, 1, 2, and 4 days after injection with 1 mmol/l siRNA using immunoblotting. *C--F*: Changes in CaMKII and phospho-CaMKII protein levels, CaMKII kinase activity, and active caspase-3 protein level in the retinas of control and diabetic groups, 2 days after the injection of 1 mmol/l αCaMKII siRNA. Each immunoblot was reprobed with α-tubulin, and levels of the other proteins were normalized to that of α-tubulin. The fold changes in protein levels compared with the controls (CTL) are indicated below the blots (*A--C*) or as a bar graph (*F*). DM, diabetic subjects. Results of the CaMKII kinase assay indicate the picomoles of phosphate incorporated into the CaMKII substrate peptide per minute per milligram of total protein (*D*). All data show representative results from four independent tests and are expressed as means ± SE (*n* = 4). \**P* \< 0.05 and \*\**P* \< 0.001 in *A*, comparing the DW-treated group with the others; \**P* \< 0.05 and \*\**P* \< 0.001 in *B*, comparing day 0 with the others; \**P* \< 0.05 and \*\**P* \< 0.001 in *C--F*, comparing the DW-treated control group with the others; †*P* \< 0.05 in *C--F*, comparing the DW- and siRNA-treated diabetic groups. C and D, control and diabetic groups at 2 months after injection with STZ or buffer; DW, distilled water.](zdb0071062000004){#F4}

A specific CaMKII inhibitor, AIP (500 μmol/l), did not affect the level of CaMKII protein but greatly diminished the level of phospho-CaMKII in a time-dependent manner in the retinas of mice 2 months after induction of diabetes ([Fig. 5](#F5){ref-type="fig"}*A*). The maximum decrease in the level of phospho-CaMKII protein was observed 2 days after the treatment at the various times studied. Finally, treatment with 500 μmol/l AIP greatly decreased the level of phospho-CaMKII protein, CaMKII kinase activity, and the level of active caspase-3 in the retinas of mice 2 months after induction of diabetes. Levels in AIP-treated diabetic mice were similar to those observed in control mice 2 days after injection (2.5-, 2-, and 5.5-fold lower, respectively, than in the PBS-treated diabetic group, *P* \< 0.05, *n* = 4) ([Fig. 5](#F5){ref-type="fig"}*B--E*). However, AIP had no effect on control mice.

![Changes in CaMKII and phospho-CaMKII protein levels, kinase activity of CaMKII, and active caspase-3 protein level after AIP treatment of retinas of mice 2 months after induction of diabetes compared with controls. AIP (2 μl) was injected into the right vitreous in the retinas, and an equal volume of saline was injected into the left vitreous humor as a control. *A*: Western blot analysis of the time-independent effect of 500 μmol/l AIP on the CaMKII protein level in the retinas of mice 2 months after induction of diabetes at 0, 1, 2, and 4 days after AIP treatment. *B--E*: Changes in CaMKII and phospho-CaMKII protein levels, CaMKII kinase activity, and active caspase-3 protein level in the retinas of control and diabetic groups 2 days after AIP treatment. Each immunoblot was reprobed with α-tubulin, and the levels of other proteins were normalized to that of α-tubulin. The fold changes in protein levels compared with the controls (CTL) are indicated below the blots (*A* and *B*) or as a bar graph (*E*). DM, diabetic subjects. Results of the CaMKII kinase assay are indicated as picomoles of phosphate incorporated into the CaMKII substrate peptide per minute per milligram of total protein (*C*). All data show representative results from four independent tests and are expressed as means ± SE (*n* = 4). \**P* \< 0.05 in *A*, comparing day 0 with the others; \**P* \< 0.05 and \*\**P* \< 0.001 in *B--E*, comparing the saline-treated control group with the others; †*P* \< 0.05 and ‡*P* \< 0.001 in *B--E*, comparing the saline- and AIP-treated diabetic groups. C and D, control and diabetic groups 2 months after injection of STZ or buffer.](zdb0071062000005){#F5}

Resveratrol treatment for 4 weeks blocked the increases in CaMKII and phospho-CaMKII protein levels and CaMKII kinase activity in the retinas of mice 2 months after induction of diabetes. Levels of CaMKII, phospho-CaMKII, and CaMKII activity were 1.7-, 1.8-, and 2-fold lower, respectively, in resveratrol-treated diabetic mice compared with CMC-treated diabetic mice (*P* \< 0.05, *n* = 4) ([Fig. 6](#F6){ref-type="fig"}*A--D*). Resveratrol also prevented the increase in the number of CaMKII and phospho-CaMKII immunopositive RGCs (arrows and arrowheads) in the retinas of mice 2 months after induction of diabetes, maintaining levels similar to those of controls. Levels of CaMKII and phospho-CaMKII were 2.2- and 3-fold lower, respectively, in resveratrol-treated diabetic mice compared with CMC-treated diabetic mice (*P* \< 0.05, *n* = 4) ([Fig. 6](#F6){ref-type="fig"}*H* and *L*).

![Effects of resveratrol on CaMKII and phospho-CaMKII protein expression and the kinase activity of CaMKII in retinas of mice 2 months after induction of diabetes compared with controls. Resveratrol (20 mg · kg^−1^ · day^−1^) was completely suspended in 0.5% CMC/0.9% saline and was administered by oral gavage once a day for 4 weeks, beginning 1 month from the last day of the fifth injection of STZ or buffer, and 0.5% CMC was used as a control. *A* shows representative immunoblots of CaMKII and phospho-CaMKII. Each immunoblot was reprobed with α-tubulin. The levels of the other proteins were normalized to that of α-tubulin, and the fold changes are indicated in *B* and *C*, respectively. Results of the CaMKII kinase assay are indicated in picomoles of phosphate incorporated into the CaMKII substrate peptide per minute per milligram of total protein (*D*). To confirm changes caused by resveratrol in CaMKII and phospho-CaMKII in neuronal cells of control and diabetic retinas, cryosections were immunostained with specific antibodies and counterstained with cresyl violet. Arrows and arrowheads indicate RGCs immunopositive for CaMKII (*E--G*) and phospho-CaMKII (*I--K*), respectively. The image of the resveratrol-treated control group was omitted from the figure because resveratrol and CMC treatment did not significantly affect control mice. The total number of these cells was counted in the GCL (∼100 μm) in four different fields from three different retinas for each group (*H* and *L*). All data show representative results from four independent tests and are means ± SE (*n* = 4). \**P* \< 0.05 and \*\**P* \< 0.001, comparing the CMC-treated control group with the others; †*P* \< 0.05 comparing the CMC- and resveratrol-treated diabetic groups. C (CTL) and D (DM), control and diabetic mice 2 months after injection of buffer or STZ; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer; RES, resveratrol. Bars, 12.5 μm. (A high-quality digital representation of this figure is available in the online issue.)](zdb0071062000006){#F6}

Lastly, we found that resveratrol effectively prevented the increase in the level of active caspase-3 protein and the number of cells co-stained for TUNEL and phospho-CaMKII (arrows in [Fig. 7](#F7){ref-type="fig"}*D* and *E*) in the retinas of mice 2 months after induction of diabetes. Levels of active caspase-3 and dying phospho-CaMKII--immunoreactive RGCs (arrowhead in insert) were 2.4- and 2.6-fold lower, respectively, in resveratrol-treated diabetic mice compared with CMC-treated diabetic mice (*P* \< 0.05, *n* = 4) ([Fig. 7](#F7){ref-type="fig"}*F*). However, resveratrol and CMC treatment did not significantly affect control or diabetic mice, respectively.

![Effects of resveratrol on cell death and RGC cells co-stained for TUNEL and phospho-CaMKII in retinas of mice 2 months after induction of diabetes compared with controls. *A* shows a representative immunoblot using antibody to active caspase-3. Each immunoblot was reprobed with α-tubulin. The levels of other proteins were normalized to that of α-tubulin, and the fold changes are indicated in *B*. To confirm the death of cells in conjunction with phospho-CaMKII expression, immunofluorescent staining of phospho-CaMKII using Alexa Fluor 488 goat anti-rabbit IgG (*green*) and TUNEL staining (*red*) were performed consecutively in the same sections, and the sections were counterstained with the nuclear marker DAPI (*C--E*). Arrows indicate TUNEL^+^ cells that are immunopositive for phospho-CaMKII in the retinas of diabetic mice without or with resveratrol. To examine whether the co-positive cells were RGC cells, we performed sequential double-immunofluorescent staining for γ-Syn, the ganglion cell marker, and phospho-CaMKII, using Alexa Fluor 350 (*blue*) and 488 (*green*) goat anti-rabbit and -mouse IgGs before TUNEL staining (*red*). The arrowheads in the insert show the triple-stained RGC cell in the diabetic retina (*D*). Image of the resveratrol-treated control group was omitted from the figure because resveratrol and CMC treatment did not significantly affect control mice. The total number of double-stained cells was counted in the GCL (∼100 μm) in four different fields from three different retinas for each group (*F*). Data are means ± SE (*n* = 4). \**P* \< 0.05 comparing the CMC-treated control group with the others. †*P* \< 0.05 comparing the CMC- and resveratrol-treated diabetic groups. C (CTL) and D (DM), control and diabetic mice 2 months after injection with buffer or STZ; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer; RES, resveratrol. Bars, 12.5 μm. (A high-quality digital representation of this figure is available in the online issue.)](zdb0071062000007){#F7}

DISCUSSION
==========

In the present study, we found that resveratrol effectively prevented diabetes-induced RGC death and CaMKII upregulation in type 1 diabetic mice.

Some investigators have suggested that neuronal damage in the retina could result from a reduction in retinal thickness, and a progressive loss of retinal structure in diabetes might contribute to the progression of diabetic neuropathy, resulting in vision loss ([@B26],[@B27]). In this study, we confirmed that diabetes induces not only a reduction in inner retina thickness, including the GCL, but also the death of RGC cells ([Fig. 1](#F1){ref-type="fig"}). It appears that the death of RGCs might be therefore linked to a decrease in the thickness of the inner retina, indicating that diabetes-induced retinal pathology occurred in our experimental model of diabetes.

CaMKII activation is involved in physiological and pathological events in neurons in an autophosphorylation-dependent manner ([@B28],[@B29]). In particular, CaMKII action in damaged retinas is involved in the cell death pathway of RGCs, resulting in visual dysfunction ([@B12],[@B13],[@B16]). In the present study, we found that both total and phospho-CaMKII protein levels were increased, along with CaMKII activity, in retinas damaged by diabetes ([Fig. 2](#F2){ref-type="fig"}). These results indicate that activation of CaMKII kinase depends on the elevated abundance of this enzyme in the diabetic retina. CaMKII and phospho-CaMKII immunoreactivity was detected only in RGCs throughout the retinas, and dying TUNEL^+^ cells in the diabetic retinas were specific to immunopositive RGCs ([Fig. 3](#F3){ref-type="fig"}). Our results are in agreement with those of many investigators who reported a proapoptotic function of CaMKII in retinal neurons ([@B12],[@B13],[@B16]). Phosphorylation of CaMKII has been known to play a pivotal role in the function of this enzyme, and CaMKII-selective siRNA ([@B16],[@B30]) and potent inhibitors of CaMKII, such as AIP ([@B10],[@B12]), have been used as tools to study the physiological effects of CaMKII. In addition, AIP is known to confer neuroprotection on RGCs by inhibiting CaMKII autophosphorylation ([@B12][@B13]--[@B14]). In the present study, CaMKII siRNA and AIP treatments effectively prevented CaMKII activation, and these treatments also effectively attenuated RGC death induced by diabetes ([Figs. 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). Together, our results indicate that diabetes-induced RGC death is primarily mediated by CaMKII overexpression and/or activation. However, CaMKII activation by phosphorylation also contributes to neuronal survival under certain conditions ([@B15],[@B16]). For instance, activation of CaMKII may be a neuroprotective response against glutamate or its analog N-methyl-[d]{.smallcaps}-aspartate (NMDA)-induced retinal neurotoxicity both in vitro and in vivo ([@B13],[@B16]). This discrepancy may be due to differences in neuronal sensitivity against different pathophysiological stimuli.

Recently, Deng et al. ([@B31]) suggested that resveratrol can partly block hyperglycemia via the enhancement of glucose uptake, and resveratrol is recognized as a potent clinical therapeutic for the treatment of diabetes-induced vascular dysfunction and cell death ([@B32][@B33]--[@B34]). Consistent with these results, we found that resveratrol significantly diminished the elevation in blood glucose levels in mice 2 months after induction of diabetes, although resveratrol-treated diabetic mice sustained a hyperglycemic state ([Table 1](#T1){ref-type="table"}). Therefore, we cannot exclude the possibility that resveratrol partially protects diabetes-induced retinal damage through the reduction of blood glucose levels but elicits effects that are not always coincident with the control of hyperglycemia.

The antidiabetic metabolic effects of resveratrol have been well documented in other organs besides the retina. Sirtuin 1 (SIRT1) and activator of AMP-activated protein kinase (AMPK), which are activated by resveratrol, have been described as key contributors to the protective effects of resveratrol in diabetic pathophysiology ([@B19][@B20]--[@B21],[@B35]). Furthermore, a recent study reported that resveratrol promotes AMPK activation by CaMK kinase (CaMKK) ([@B36]). In a preliminary study, we examined effects of resveratrol on SIRT1 and AMPK levels in retinas of mice 2 months after induction of diabetes. Finally, we found that neither diabetes nor resveratrol affect SIRT1 action in our animal model and that phospho-AMPK levels were greatly lower in the retinas of diabetic mice than controls, and this decline was reversed by resveratrol treatment; however, phospho-AMPK levels in the retinas of resveratrol-treated diabetic mice were still in a state of significant decline compared with controls (all data not shown). These results suggest that resveratrol partly contributes to AMP kinase induction in our model; however, in the present study, activation of CaMKII induced by diabetes in mouse retinas was prevented and preserved at a basal level by resveratrol treatment ([Figs. 6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). Therefore, we suggest that AMPK is not likely to be a major target of resveratrol in CaMKII-mediated cell death in our animal experimental model. The discrepancy between our results and those of other researchers may be due to differences in the pathophysiological conditions mediated by diabetes.

Recent studies have shown that resveratrol prevents RGC damage in response to various stresses, including oxidation and inflammation ([@B22],[@B23]). Levels of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), regarded as indicators of these stresses, are increased in diabetic retinas in our model; these immunoreactivities were specific to vessels in retinas but not to neurons, and resveratrol decreases the induction of COX-2 and iNOS in diabetic retinas (data not shown). These data show that iNOS and COX-2 do not contribute to prevent retinal neurons from diabetes-induced cell death in our animal model, although we cannot rule out the possibility that resveratrol may affect biological processes through a reduction of oxidative stress and inflammation. Further, the present study showed that the oral administration of resveratrol effectively blocks the activation of CaMKII and RGC death in retinas damaged by diabetes ([Figs. 5](#F5){ref-type="fig"}[](#F6){ref-type="fig"}--[7](#F7){ref-type="fig"}). Xu et al. ([@B37]) demonstrated that curcumin, another polyphenol with resveratrol-like physiological properties, regulates both CaMKII action and CaMKII-mediated RGC loss. Many studies have assessed the neuroprotective effects of natural polyphenolic components, including resveratrol, on chronic diseases such as diabetes ([@B22],[@B23],[@B37][@B38]--[@B39]). In addition, recent reports have indicated that a voltage-gated calcium channel can modulate calcium-dependent gene expression, including CaMKII, via activity-dependent transcriptional regulation ([@B40]) and that activation of CaMKII by voltage-gated calcium channels might contribute to the death of neuronal cells, including RGCs ([@B41],[@B42]). However, considerable evidence has suggested that the protective effects of resveratrol from several stresses may be related to the direct inhibition of Ca^2+^ influx through the blockade of a voltage-gated calcium channel ([@B43],[@B44]). Accordingly, we suggest that resveratrol might control CaMKII expression and activity through interference of a calcium- and voltage-gated calcium channel--dependent process.

Taken together, our data show that CaMKII is a potential target for the treatment of vision loss due to diabetes-induced neuropathy, and resveratrol is one such molecule that elicits protective effects against diabetes-induced retinal neuronal death via CaMKII suppression.
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